Actively Recruiting
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
Led by West China Hospital · Updated on 2025-12-19
30
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.
CONDITIONS
Official Title
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years
- First diagnosis of Hepatocellular Carcinoma (HCC) without recurrence
- Single tumor with diameter 5 cm or less
- Tumor assessed as safely resectable by at least two senior liver surgeons
- No distant metastasis shown on chest CT and abdominal contrast-enhanced CT
- Child-Pugh Class A liver function
- Patient or legal guardian can understand the study and provide informed consent
You will not qualify if you...
- Postoperative pathology shows cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma
- Presence of tumor thrombus in portal vein, hepatic vein, or bile duct
- History of other cancers except cured carcinoma in situ of cervix or certain skin cancers
- Evidence of residual tumor, recurrence, metastasis, lymph node metastasis, or positive surgical margins
- Moderate to severe ascites needing therapeutic drainage or Child-Pugh score over 7 except minor ascites without symptoms
- Uncontrolled or moderate/large pleural or pericardial effusion
- Severe heart, lung, or kidney dysfunction
- Ruptured liver cancer requiring emergency surgery
- Patient or family unable to understand study conditions and objectives
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
J
Jiwei Huang Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here